New call-to-action
New call-to-action
New call-to-action

Foundation for Prader-Willi Blog | Research (14)

Categories

New Study of ARD-101 Now Enrolling Participants Ages 17-65

ARD-101 is a new, oral therapeutic that has shown promising activity in reducing appetite and promoting weight loss in preclinical (animal model) studies.
February 4, 2022 Read More

Topics: Research, Clinical Trials

Sensory Integration for Children with PWS [2021 CONFERENCE VIDEO]

In this 60‑minute video, Janice Agarwal, a Pediatric Physical Therapist, explains how children with PWS have decreased sensory awareness and how you can help your child with sensory integration. The session includes Q&A from participants in the 2...
February 3, 2022 Read More

Topics: Research, Family Conference

What's Happening In PWS Research? [2021 CONFERENCE VIDEO]

In this 67‑minute video, Dr. Theresa Strong and the FPWR Research Team share highlights of projects we are currently advancing. The session includes Q&A from participants in the 2021 FPWR Virtual Conference.
January 25, 2022 Read More

Topics: Research, Family Conference

Newborn Screening Test for PWS Paves the Way for Earlier Diagnosis

Research at a Glance: A new test, funded in part by FPWR, has been designed to simultaneously screen newborns for three rare genetic disorders In a recent study, the test was found to be feasible, reliable, and scalable Screening for Prader Willi, An...
January 25, 2022 Read More

Topics: Research

Encouraging Update from Soleno Therapeutics Regarding DCCR

Soleno Therapeutics has provided an update following recent interactions with the U.S. Food and Drug Administration (FDA) regarding the development of once-daily DCCR (diazoxide choline) extended-release tablets for the treatment of Prader-Willi synd...
January 24, 2022 Read More

Topics: Research, Clinical Trials

Levo Therapeutics Receives Complete Response from FDA Regarding Carbetocin NDA

Levo Therapeutics, announced today that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for LV-101 (intranasal carbetocin) as a treatment for hyperphagia, anxi...
January 18, 2022 Read More

Topics: Research

Saniona Initiates Phase 2b Clinical Trial of Tesomet for PWS

Saniona, a clinical-stage biopharmaceutical company focused on rare diseases, has announced the initiation of a Phase 2b clinical trial of Tesomet in patients with Prader-Willi syndrome (PWS).
January 7, 2022 Read More

Topics: Research, Clinical Trials

Standards of Care for Children and Adults with PWS [2021 CONFERENCE VIDEO]

In this 1-hour video, Dr. Jessica Duis, Clinical Geneticist from Children's Hospital Colorado explains standards of care for children and adults with PWS. The session includes Q&A from participants in the 2021 FPWR Virtual Conference.
December 20, 2021 Read More

Topics: Research, Family Conference

Standards of Care for Children Ages 0-2 With PWS [2021 CONFERENCE VIDEO]

In this 1-hour video, Dr. Jessica Duis, Clinical Geneticist from Children's Hospital Colorado explains standards of care for children ages 0-2 with PWS. The session includes Q&A from participants in the 2021 FPWR Virtual Conference.
December 14, 2021 Read More

Topics: Research, Family Conference

About FPWR

The Foundation for Prader-Willi Research (federal tax id 31-1763110) is a nonprofit corporation with federal tax exempt status as a public charity under section 501(c)(3).

4star120x60

NORD_MembershipLogo_Platinum_2021

excellence-in-giving-logo

Main Menu

Our Mission

The mission of FPWR is to eliminate the challenges of Prader-Willi syndrome through the advancement of research and therapeutic development.

Contact Us

Foundation for Prader-Willi Research
Phone: 888-322-5487
Email: info@fpwr.org

FPWR
440 N Barranca Ave #3620
Covina, CA 91723

Copyright © 2020. All Rights Reserved. Terms of Use. Privacy Policy. Copyright Infringement Policy. Disclosure Statement.